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ADDITION OF CLOFARABINE TO TLI/ATG CONDITIONING: IMPACT ON
IMMUNE RECONSTITUTION AND CLINICAL OUTCOMES
Glotzbecker, B.1,2, Mills, H.1, Rosenblatt, J.1, Joyce, R.1, Levine, J.1,
Tzachanis, D.1, Stevenson, M.1, Attar, E.3, Ballen, K.3, Chen, Y.-B.3,
Boussiotis, V.1, Zwicker, J.1, Luptakova, K.1, Arnason, J.1, Bonhoff, J.1,
Delaney, C.1, Conway, K.1, Giallombardo, N.1, Mortellite, J.1,
Fitzgerald, D.1, O’Brien, S.1, McMahon, C.1, Vasir, B.2,
Stroopinsky, D.1, Spitzer, T.3, Avigan, D.1 1Beth Israel DeaconessMedical
Center, Boston, MA; 2Dana Farber Cancer Institute, Boston, MA; 3Mas-
sachusetts General Hospital, Boston, MA
The use of reduced intensity conditioning with total lymphocyte
irradiation (TLI) and anti-thymocyte globulin (ATG) in preparation
for allogeneic transplantation has been shown to minimize the risk of
GVHD through biasing of T cell reconstitution towards an inhibi-
tory phenotype.However, disease relapse remains a concern. Clofar-
abine (Clo) is a second generation nucleoside analog with efficacy in
hematological malignancies. In this study, we examined the combi-
nation of Clo, TLI and ATG with respect to T cell reconstitution
and transplant outcomes. Sequential cohorts of 5 patients were
treated with TLI and ATG alone or in conjunction with 20 mg/
m2, 30 mg/m2 or 40 mg/m2 of Clo for 5 days. Twenty patients
have been enrolled (5 AML/MDS, 2 ALL, 6 lymphoma, 2 CLL, 5
myeloma) and received HLA matched peripheral blood stem cells
from related (N5 11) or unrelated donors (N5 9). Of 19 evaluable
patients, 15 are alive with a median follow up of 665 days. Day 100
mortality was 0% for TLI and ATG and 10% for those receiving
Clo. The maximum tolerated dose (MTD) of Clo was 30 mg/m2.
Mean bone marrow donor chimerism was 92.5% at Day 30. T cell
reconstitution studies demonstrated a decrease in CD4+ cells to
\200 cells/uL persisting for more than 6 months, and a more than
two fold increase in circulating CD56+ NK cells. No significant de-
crease in CD8 T cells in the early post-transplant period was seen.
The mean percentage of regulatory T cells (CD4+/25+/FoxP3+)
rose in the early post-transplant period following TLI and ATG
(5.5 to 14.2% from baseline to day 30; p 5 0.015), but not in those
receiving Clo (8.1 to 6%; p 5 0.15). A two fold increase in CD8+
T cells expressing IL-4 was seen at Day 30 in patients receiving
TLI and ATG alone (p 5 0.04); but not following Clo, TLI and
ATG. Consistent with these findings, the incidence of grade II-IV
GVHD was 0% and 42% in those receiving TLI and ATG alone
or with Clo, respectively. cGVHD was seen in 20% and 42% of pa-
tients, respectively. In contrast, disease progression was seen in 60%
of patients receiving TLI and ATG alone as compared to 27% re-
ceiving Clo, TLI, and ATG. In summary, the addition of Clo to
TLI and ATG conditioning resulted in a decrease in circulating reg-
ulatory T cells, decreased CD8+ T cell expression of IL-4, and was
associated with an increased risk of GVHD and the potential de-
crease in the risk of relapse in this pilot study.28
FAVORABLE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT IN
SEVERE THALASSEMIA PATIENTS OLDER THAN 10 YEARS BY USING RE-
DUCED INTENSITY CONDITIONING REGIMEN
Hongeng, S., Pakakasama, S., Anurathapan, U., Sirachianan, N.,
Songdej, D., Chuansumrit, A. Ramathibodi Hosopital, Mahidol Univer-
sity, Bangkok, Thailand
CIBMTR has reported that severe thalassemia patients who were
older than 7 years and hepatomegaly, had poor outcome of trans-
plantation (DFS 5 55%) (Blood; 2011). We therefore would like
to report our new approach of transplant for this group of patients
with our reduced intensity conditioning regimen (RIC). We re-
viewed 20 severe thalassemia patients older than 10 years and hepa-
tomegaly (liver 2 cm below coastal margin). These patients
underwent transplantation with our RIC which consisted of busul-
fan, fludarabine, antithymocyte globulin, 6 TLI. All patients re-
ceived peripheral blood stem cells. Prior to transplant, all of them
at least for 1 year went on a pre-transplant management program in-
cluding hypertransfusion, iron chelation and oral hydroxyurea. We
also conducted a post transplant management by using chimerism
study followed by various strategies such as reducing immusuppres-sive drug and infusing donor lymphocyte or peripheral blood setm
cell to prevent further graft loss in case of mixed chimersim within
the first 100 days after transplant. Of 20 patients, 17 received related
and 3 received unrelated donor stem cells. Thalassemia free and
overall survivals were 92%. The rejection and mortality rates were
8%.We suggest that our high risk severe thalassemia can acheive a fa-
vorable outcome of transplant with our RIC approach especially our
pre and post transplant management.29
SHORT-TERM IMMUNOSUPPRESSIVE AGENTS FOR GRAFT-VERSUS-HOST
DISEASE (GVHD) PROPHYLAXIS AFTER DONOR LYMPHOCYTE INFUSION
(DLI) HAVE NO INFLUENCE ON GRAFT-VERSUS-LEUKEMIA (GVL) EF-
FECTS AND COULD IMPROVE LEUKEMIA-FREE SURVIVAL IN HAPLOI-
DENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Yan, C., Liu, D., Xu, L., Chen, H., Han, W., Wang, Y., Liu, K.,
Huang, X. Peking University People’s Hospital, Peking University Insti-
tute of Hematology, Beijing, China
Background:The use of graft-versus-host disease (GVHD) prophy-
laxis after donor lymphocyte infusion (DLI) could reduce the inci-
dence of severe DLI-associated acute GVHD in haploidentical
hematopoietic stem cell transplantation (HSCT), but the influence
of GVHD prophylaxis on the graft-versus-leukemia (GVL) effects
has not been investigated.
Methods: 158 patients receiving DLI after haploidentical HSCT
were enrolled. Specifically, 46 received therapeutic DLI because of
hematological or extramedullary relapse after HSCT; 46 received
pre-emptive DLI because of minimal residual disease (MRD) after
HSCT; and 66 received prophylactic DLI because of a high-risk dis-
ease status pre-HSCT.
Results: Compared with using GVHD prophylaxis 4 - 6 weeks and
less than 4 weeks, prophylaxis more than 6 weeks had no influence on
relapse after DLI (2-year: 24.2%, 42.3% and 45.6%, P5 0.106) and
resulted in superior overall survival (2-year OS: 53.4%, 34.5% and
29.2%, P 5 0.037) and leukaemia-free survival (2-year LFS:
45.2%, 32.1% and 26.1%, P 5 0.043). Furthermore, whether for
pre-emptive or prophylactic DLI, there were trends that OS (pre-
emptive (2-year): 66.7%, 44.4% and 40.7%, P5 0.754; prophylactic
(2-year): 54.9%, 30.5% and 10.1%, P 5 0.013) and LFS (pre-emp-
tive (2-year): 66.7%, 38.9% and 39.7%, P 5 0.568; prophylactic
(2-year): 30.0%, 29.7% and 8.7%, P 5 0.042) in patients with pro-
phylaxis for more than 6 weeks were all superior to that in other pa-
tients. For therapeutic DLI, there was also a trend that the 1-year OS
in patients with prophylaxis for more than 6 weeks was superior to
that in other patients (50.0%, 28.6% and 39.2%, P 5 0.986) and
the 1-year LFS was similar to the result in other patietns (25.0%,
21.4% and 29.9%, P 5 0.785).
Conclusion: This study for the first time demonstrated that in
HLA-haploidentical HSCT, DLI with GVHD prophylaxis for
more than 6 weeks have no influence on GVL effects at the same
time could reduceDLI-associated acuteGVHD, and finally improve
survival.30
ALLOGENEIC STEM CELL TRANSPLANTATION FOR KOREAN PNH
PATIENTS
Jang, J.H.1, Lee, J.W.2, Kim, J.S.3, Yoon, S.S.4, Lee, J.H.5, Kim, Y.K.6,
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Introduction: PNH is a debilitating and life-threatening hemato-
poietic stem cell disorder characterized by chronic hemolysis leading
to significant morbidities, end organ damage and mortality in PNH
patients. Even though there are different therapeutic approaches for
PNH, allotransplantation can cure the disease but cause several
S214 Oral Presentationscomplications. We reports here 33 Korean PNH patients who un-
derwent allotransplantation.
Aims: To understand the impact of allotransplant in Korean PNH
patients, we retrospectively analyzed medical charts of 33 PNH pa-
tients from national registry in Korea.
Results: Patient ages ranged from 15 to 56 years (median 29 years,
male 14, female 19). Classic PNH were 12 patients and PNH with
bone marrow disease were 21. Median LDH level at the time of di-
agnosis was 1159 IU/L (297  7699). The source of stem cells were
bone marrow in 13 patients and peripheral blood in 20 patients. Sib-
ling donor were 23 and unrelated donor were 10. Conditioning reg-
imens consisted of BuCy or Cy/TBI (n5 14), fludarabine containing
reduced intensity regimen (n 5 18), or other. All patients attained
successful leukocyte engraftment (median 13 days, range 1030
days) and platelet engraftment (median 17 days, range 1148
days). Grade IIIV acute GVHD were in 19 patients (skin 13, liver
3, gut 3). Grade IIIV chronic GVHD were in 13 patients (limited
10, extensive 3). With a median follow-up of 82.6 months (range,
19.5 160.2 months), 26 patients are alive with CR. Seven patients
were died after transplantation due to pulmonary hemorrhage (n 5
2), sepsis (n 5 2), GVHD/multi organ failure n 5 2), or massive
thromboembolism (n 5 1). Patients with reduced intensity condi-
tioning regimen had a better survival than patients with conventional
conditioning regimen (p 5 0.027). There were no survival differ-
ences between classic PNH patients and PNH patients with BMD.
There were also no differences between two groups categorized by
PNH clone sizes, stem cell sources, and PNH related symptoms.
Conclusion: Our data demonstrates that reduced intensity condi-
tioning regimen is suitable for allogeneic stem cell transplatation
of PNH patients.31
A RANDOMIZED PHASE III TRIAL INVESTIGATING 2 Gy TBI VS. Flu/2 Gy
TBI CONDITIONING FOR HLA-MATCHED RELATED DONOR HEMATOPOI-
ETIC CELL TRANSPLANTATION (HCT): TEMPO OF CD3 AND NK CELL EN-
GRAFTMENT DETERMINES RELAPSE AND PROGRESSION FREE SURVIVAL
IN PATIENTS WITH HEMATOLOGIC
Kornblit, B.1, Storer, B.1, Storb, R.F.1, Hari, P.2, Vucinic, V.3,
Maziarz, R.T.4, Chauncey, T.1,5, Pulsipher, M.A.6, Bruno, B.7,
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Maloney, D.G.1, Sandmaier, B.M.1 1Fred Hutchinson Cancer Research
Center and University of Washington, Seattle, WA; 2Medical College of
Wisconsin, Milwaukee, WI; 3University of Leipzig, Leipzig, Germany;
4Oregon Health and Science University School of Medicine, Portland,
OR; 5VA Puget Sound Health Care System, Seattle, WA; 6University
of UtahMedical Center, Salt Lake City, UT; 7University of Torino School
of Medicine, Torino, Italy; 8LDS Hospital, Salt Lake City, UT; 9Univer-
sity of TubingenMedical Center, Tubingen, Germany; 10University of Co-
logne, Cologne, Germany; 11University of Calgary, Calgary, Canada
Nonmyeloablative conditioning with fludarabine (Flu) and 2 Gy
TBI with MMF/CSP postgrafting immunosuppression results in
reliable allogeneic engraftment. A retrospective analysis of pts
conditioned with 2 Gy TBI alone prior to receiving PBSC from
HLA-matched related donors showed that rejection primarily oc-
curred in pts who pre-HCT had not received intensive chemother-
apy. Addition of Flu (30 mg/m2/d x 3 d) in a subsequent cohort
seemed associated with increased nonrelapse mortality (NRM).
Here, we report results of a phase III randomized multi-institutional
trial that asked whether Flu was needed in heavily pretreated pts to
assure sustained engraftment of HLA-matched related grafts.
Immunosuppression included MMF (28 d) and CSP (180 d).
Eighty-five pts with AML (n 5 15), NHL (n 5 32), MM (n 5 9),
CLL (n 5 9), MDS (n 5 4), and HL (n 5 16) were randomized to
be conditioned with either 2 Gy TBI alone (TBI; n 5 44) or Flu/
2 Gy TBI (Flu/TBI; n5 41) with stratification by transplant center,
disease risk and prior high dose HCT. Pts received G-PBMC con-
taining a median of 7.9 x106 CD34 and 3.6 x108 CD3 cells/kg.
The median age was 55 (range, 17–73) years. Forty-five had failed
previous autologous (n 5 41) or allogeneic (n 5 4) high-dose
HCT. The primary endpoint was NRM with secondary endpoints
of survival, relapse/progression, GHVD and rejection. Median
follow-up was 4.6 (range, 0.6–7) years.Table. Transplant outcomes after HLA-matched related do-
nor HCT in patients conditioned with 2 Gy TBI only or with
fludarabine 90 mg/m2
TBI Flu/TBI(n 5 44) (n 5 41) PRejections (number of pts) 2 0 0.50GVHD Grade II-IV acute @ 120 d, % 34 46 0.23Grade III-IV acute @ 120 d, % 9 7 0.82Chronic @ 3 years 49 71 0.21Donor
chimerismT-cell day 28, %, median 61 90 <0.0001T-cell day 84, %, median 68 92 <0.0001NK-cell day 28, %, median 75 96 0.0005Nonrelapse mortality @ 3 years, % 17 14 0.35Relapse/progression @ 3 years, % 51 33 0.04Relapse mortality @ 3 years, % 32 22 0.10Overall survival @ 3 years, % 52 65 0.09Progression-free survival @ 3 years, % 32 53 0.03No significant differences between arms were observed for NRM
(3 year; TBI 17%, Flu/TBI 14%), grade II-IV acute (TBI 34%, Flu/
TBI 46%) or chronic GVHD (TBI 49%, Flu/TBI 71%). Rejection
was only observed in 2 TBI pts. The 3 year survival was 52% and
65% in TBI and Flu/TBI pts (p 5 0.09), respectively, with a higher
incidence of relapse/progression (TBI 51%, Flu/TBI 33%, p5 0.04)
and relapse related mortality (TBI 32%, Flu/TBI 22%, p 5 0.10),
translating into a significantly lower progression-free survival (TBI
32%, Flu/TBI 53%, p 5 0.03) in TBI pts. Compared to TBI pts,
the CD3 donor chimerisms on d28 and d84 were significantly higher
in Flu/TBI pts as was the NK cell chimerism on d28. Even though
low rates of rejection and similar incidences of NRM were observed
in both arms, Flu/TBI pts had better progression free survival. In
view of the significantly higher CD3 and NK donor chimerism in
Flu/TBI pts, the result of this randomized trial demonstrate the im-
portance of Flu in augmenting the graft versus tumor effect, by en-
suring prompt and durable high level donor engraftment early
post-transplant.
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ADENOVIRUS VIREMIA IN PATIENTS WITH CLINICAL SYMPTOMS AFTER
T-CELL DEPLETED HSCT: RATES OF ADENOVIRUS DISEASE AND OUT-
COMES
Lee, Y.J.1, Chung, D.1, Xiao, K.2, Small, T.1, Papadopoulos, E.1,
Jakubowski, A.A.1, Papanicolaou, G.A.1 1Memorial Sloan-Kettering
Cancer Center; 2Columbia University
Background: Invasive ADV infections are a known cause of mortal-
ity in HSCT.High or rising ADV viral loads are thought to be a pre-
dictor of ADV disease. T-cell depletion (TCD) reduces the risk of
graft vs host disease, but has been associated with an increased inci-
dence and complications of certain viral infections.We examined the
outcomes of patients found to have ADV viremia after TCDHSCT
at our institution.
Method: A retrospective review was conducted on 401 adult and pe-
diatric patients who received TCD HSCTs at MSKCC from Jan
2006 through March 2011. Follow up ranged from (6 months - 5
years). Quantitative ADV PCR in whole blood was evaluated by
the treating physicians based on clinical symptoms. ADV viremia
was defined as at least 1 positive study of $ 1,000 copies/ml or .2
consecutive positive studies of $500 copies/ml/ ADV PCR. Defini-
tions were: early ADV viremia - first positive ADV PCR at\ 180
days post HSCT, and high viral load (HVL) as $ 10,000 copies/
ml. ADV Disease: Definite: presence of typical adenovirus nuclear
inclusions on histopathology, and/or positive culture from sterile
site (other than blood), or both. Probable adenovirus: ADV viremia
and associated clinical symptoms without other identifiable causes).
Results: The 401 TCD HSCTs included 23.7% children, 90% pe-
ripheral blood stem cell grafts, and 63.1% unrelated donors, median
age 47.5 yrs (range 0.1-73 yrs). Thirty five (8.7%) patients were di-
agnosed with ADV viremia at a median of 93 days (range 15 - 674)
post HSCT. The incidence of diagnosed ADV viremia in this group
was higher in pediatric vs adult pts (15.3 vs 6.2%). ADVwas detected
in 35/401 (8.7%) (6.2% adult and 15.3% pediatric) pts a median of
